“I think it’s really important that people keep signing up to these type of trials to push research forward.”
A trial looking at treatment for the Ewing sarcoma family of tumours (EURO-EWING 99)
Cancer type:
Status:
Phase:
This trial looked at chemotherapy, surgery and radiotherapy for the Ewing sarcoma family of tumours. It was for children, young people and adults up to the age of 50. This trial was supported by Cancer Research UK.
More about this trial
- which treatments work best for Ewing sarcoma family of tumours
- more about the side effects
Summary of results
- the combination of vincristine, dactinomycin and cyclophosphamide (VAC) may be as good as vincristine, dactinomycin and ifosfamide (VAI)
- radiotherapy after chemotherapy was useful for some patients
- the combination of bulsulfan and melphalan (BuMel) worked better than vincristine, dactinomycin and ifosfamide (VAI) for some people whose sarcoma is likely to respond less well to treatment
- in 2014 they published results comparing VAC and VAI chemotherapy
- in 2016 they published results about how well radiotherapy worked
- in 2018 they published results comparing VAI and BuMel chemotherapy
- 431 had vincristine, dactinomycin and cyclophosphamide (VAC)
- 425 had vincristine, dactinomycin and ifosfamide (VAI)
- 114 out of 431 (26%) who had VAC
- 102 out of 425 (24%) who had VAI
- 88 out of 431 people (20%) who’d had VAC
- 83 out of 425 people (20%) who’d had VAI
- more people who had VAC chemotherapy had a drop in white blood cells and blood clotting cells (platelets)
- more people who had VAI had problems with kidney function
- the risk of infection was similar in the two groups
- 142 had radiotherapy
- 457 didn’t have radiotherapy
- 13 out of 142 people (9%) who’d had radiotherapy
- 54 out of 457 people (12%) who hadn’t had radiotherapy
- 1 out of 65 people (2%) who’d had radiotherapy
- 35 out of 299 people (12%) who hadn’t had radiotherapy
- 118 had vincristine, dactinomycin and ifosfamide (VAI)
- 122 had busulfan and melphalan (BuMel)
- 60 out of 118 people (51%) who’d had VAI
- 45 out of 122 people (37%) who’d had BuMel
- 53 out of 118 people (45%) who’d had VAI
- 37 out of 122 people (30%) who’d had BuMel
- those that affected the digestive system, such as sore mouth, diarrhoea and being sick
- changes in liver proteins (enzymes)
- a drop in red blood cells, white blood cells and clotting cells (platelets)
Recruitment start:
Recruitment end:
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Chief Investigator
Dr Bernadette Brennan
Supported by
Other information
This is Cancer Research UK trial number CRUK/02/014.
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040